Your browser doesn't support javascript.
loading
Crimean-Congo Hemorrhagic Fever Beyond Ribavirin: A Systematic Review.
Fabara, Stephanie P; Ortiz, Juan Fernando; Smith, Derrick Wayne; Parwani, Jashank; Srikanth, Sashwath; Varghese, Teresa; Paez, Maria; Desai, Prarthana; Tirupathi, Raghavendra.
Afiliación
  • Fabara SP; Internal Medicine, Universidad Catolica de Santiago de Guayaquil, Guayaquil, ECU.
  • Ortiz JF; Neurology, Universidad San Francisco de Quito, Quito, ECU.
  • Smith DW; Neurology, Larkin Community Hospital, Miami, USA.
  • Parwani J; Health Sciences, American University of the Caribbean, Pembroke Pines, USA.
  • Srikanth S; Neurology, Lokmanya Tilak Municipal Medical College, Mumbai, IND.
  • Varghese T; Internal Medicine, SRM Medical College Hospital and Research Center, Chennai, IND.
  • Paez M; Medicine, Kasturba Medical College, Manipal University, Manipal, IND.
  • Desai P; General Medicine, Pontificia Universidad Catolica del Ecuador, Quito, ECU.
  • Tirupathi R; Internal Medicine, Gujarat Medical Education & Research Society (GMERS) Medical College, Vadodara, IND.
Cureus ; 13(9): e17842, 2021 Sep.
Article en En | MEDLINE | ID: mdl-34557373
Crimean-Congo hemorrhagic fever (CCHF) is a tick-borne virus endemic to a vast geographical area spanning from Africa to the shores of the Mediterranean Sea and north to the Balkans. The infection carries a high case fatality rate, which prompts the development of new treatment and prophylactic measures. This review explores the different treatment and prophylactic measures found in recent literature. For this purpose, we used Medical Subject Headings (MeSH) as well as PubMed advanced search. The inclusion criteria included full-text studies conducted on humans and in the English language. We found that plasma exchange was associated with a decrease in mortality rates. Similarly, the use of immunoglobulins proved effective in decreasing the severity and mortality risk. Ribavirin use was determined as a post-exposure prophylaxis drug with no statistically significant difference in oral or intravenous routes of administration. More studies should be conducted on CCHF as the number of outbreaks and endemic areas seem to be on the rise. For the time being, supportive therapy along with adjuvant antivirals appear to be the main course of management of CCHF. However, the need for definitive therapeutic agents and guidelines is warranted.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline / Systematic_reviews Idioma: En Revista: Cureus Año: 2021 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline / Systematic_reviews Idioma: En Revista: Cureus Año: 2021 Tipo del documento: Article Pais de publicación: Estados Unidos